

August 8, 1968

Dr. G. B. Blane
Department of Pharmacology
Research Laboratories
Reckitt & Sons, Ltd.
Hull, England

Dear Dr. Blane:

For the past two years we have studied the conditioning theory of narcotic addiction as expressed by Wikler. We started with cyclazocine and carried out some studies with naloxone.

Cyclazocine has the disadvantages of a narrow therapeutic index and naloxone appears to have a very short duration of action. Despite these limitations, both treatments appear to follow the deconditioning model and have shown sufficient promise to excite us to continue. We are interested, however, in any other narcotic antagonists which can be of longer duration of action and with fewer side effects.

I am enclosing copies of our reports which will bring you up-to-date in our present program.

In the event that 5050-M, or other active antagonists goes to human trial, we would be anxious to test it.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp